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INTRODUCTION
Both retroviruses and long terminal repeat (LTR) retro-
transposons use cellular tRNAs as primers for reverse tran-
scription during their replication cycles. In retroviruses, primer
tRNA is selectively packaged into the virion, where it is placed
onto the primer binding site (PBS) of the viral RNA genome
and used to prime the reverse transcriptase (RT)-catalyzed
synthesis of minus-strand cDNA. Studies of how these pro-
cesses are carried out in different retroviral groups have re-
vealed both similarities and differences. Although less exten-
sively studied, a comparison of processes occurring in LTR
retrotransposons with similar processes occurring in retrovi-
ruses is also informative and is included herein. For an excel-
lent summary of earlier work on retroviral primer tRNAs, the
reader is referred to the review by Waters and Mullin (83).
Later reviews on this topic include those by Litvak et al. (48),
Marquet et al. (54), and Leis et al. (41), while reviews provid-
ing information on retrotransposon primer tRNAs include
those by Voytas and Boeke (78) and Sandmeyer and Menees
(68).
Retroviruses can be divided into three major subfamilies,
oncoviruses, lentiviruses, and spumaviruses, while retrotrans-
posons can be placed into two categories named after the
prototypic Drosophila elements copia and gypsy (68). The rep-
lication cycles of retroviruses and LTR retrotransposons show
strong similarities, as shown in Fig. 1. Both retroviruses and
retrotransposons code for Gag and Gag-Pol proteins. Retro-
viral Gag proteins contain sequences for matrix (MA), capsid
(CA), and nucleocapsid (NC) proteins, while retrotransposon
Gag proteins contain sequences for CA and, sometimes, NC
proteins (68). Both retroviral and retrotransposon pol genes
code for protease (PR), RT, and integrase (IN). copia- and
gypsy-like elements can be distinguished from each other by
major differences in RT sequences (89), and while in copia-like
elements the IN gene precedes the RT-RNase H gene, in
gypsy-like elements the RT-RNase H sequence precedes the IN
sequence (18, 73), as in retroviruses. Many types of retrovi-
ruses have an extracellular stage in their life cycle, and this is
associated with the presence of envelope protein (Env). The
replication cycle of most retrotransposon elements produces
an intracellular virus-like particle (VLP) which contains no
Env protein. However, some gypsy elements do have an extra-
cellular stage, and this is associated with the presence of Env
protein (36, 60). Some of the similarities and differences
among retroviruses and retrotransposons relevant to this re-
view are summarized in Table 1.
The full-length RNA transcribed from proviral or retro-
transposon elements codes for Gag and Gag-Pol precursor
proteins, which in the cytoplasm assemble into particles that
package the full-length mRNA, as well as low-molecular-
weight tRNA. In both particle types, the Gag and Gag-Pol
precursor proteins are cleaved by a viral protease to the final
mature proteins. The reverse transcription of the packaged
RNA in both retroviruses and retrotransposons is primed by a
cellular tRNA, and the resulting double-stranded cDNA is
integrated into the host cell DNA by viral- or retrotransposon-
encoded IN.
THE PRIMER tRNAS
In both retroviruses and retrotransposons, cDNA synthesis
is initiated from the PBS near the 59 end of the packaged RNA.
The primer tRNAs used in retroviruses and retrotransposons
are listed in Table 1 and in many cases have been identified
only by the PBS sequence. tRNATrp is the primer for all mem-
bers of the avian sarcoma virus (ASV)-avian leukosis virus
(ALV) group examined to date (17, 21, 63, 70, 83, 84). There
are three major tRNALys isoacceptors in mammalian cells (65).
tRNA1,2
Lys, representing two tRNALys isoacceptors differing by 1
bp in the anticodon stem, is the primer tRNA for several
retroviruses, including Mason-Pfizer monkey virus and human
foamy virus (HFV) (41). tRNA3
Lys serves as the primer for
mouse mammary tumor virus (62, 82) and the lentiviruses,
such as equine infectious anemia virus, feline immunodefi-
ciency virus, simian immunodeficiency virus, and human im-
munodeficiency virus types 1 and 2 (HIV-1 and HIV-2) (41).
tRNAPro is the common primer for Moloney murine leukemia
virus (Mo-MuLV) (20, 61, 77), but murine retroviruses have
also been reported to make use of several alternate tRNAs as
primers. For example, a recombinant MuLV that replicates
with wild-type kinetics, but uses tRNA1
Gln as a primer, was
isolated by Colicelli and Goff (10), and endogenous murine
retroviruses that have PBSs complementary to tRNA3
Lys,
tRNAPhe, and tRNAGly have also been reported (10). The
specificity of interaction in vitro between RT and the cognate
primer tRNA appears to be greater for HIV (6, 67), Rous
sarcoma virus (RSV), and avian myeloblastosis virus (AMV)
(11, 23, 59) than for MuLV (58).
Retrotransposons and retroviruses use different primer
tRNAs for reverse transcription, and for some retrotrans-
posons only a tRNA fragment is used as the primer (68, 78). In
the yeast Saccharomyces cerevisiae, there are five known Ty
retrotransposons: Ty1 (copia), Ty2 (copia), Ty3 (gypsy), Ty4
(copia), and Ty5 (copia). The first three have primer binding
sites, complementary to the 39 terminus of tRNAi
Met, of 10, 10,
and 8 bases in length, respectively. While this is short com-
pared to 18-base retroviral PBSs, it has been reported that in
* Corresponding author. Mailing address: Lady Davis Institute for
Medical Research, Jewish General Hospital, 3755 Cote Ste-Catherine
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HIV-1 a deletion of 12 of the 18 nucleotides at the 39 end of
the PBS still allows sufficient complementarity for efficient
reverse transcription (80). The PBS in Ty4 is complementary to
the 39 18 bases of tRNAAsn. The primer binding site in the Ty5
element is complementary to a 13-base internal fragment
(which includes the anticodon loop) of tRNAi
Met (78). For the
Drosophila copia element, a 39-nucleotide fragment from the
59 region of Drosophila tRNAi
Met is used as the primer for
copia minus-strand cDNA synthesis by RT (35). The Drosoph-
ila gypsy and gypsy-like elements whose sequences are known
include 17.6, 297, tom, and gypsy. For the first three of these,
the PBS is complementary to the 39 18 bases of tRNASer, while
the primer binding site of the gypsy element is complementary
to the 39 11 bases of tRNALys.
VIRAL PROTEIN-tRNA INTERACTIONS INVOLVED IN
THE SELECTIVE PACKAGING AND GENOMIC
PLACEMENT OF PRIMER tRNAS
Primer tRNA is selectively packaged during the assembly of
retroviruses or VLPs. In general, the term “selective packaging
of tRNA” refers to the increase in the percentage of the low-
molecular-weight RNA population representing primer tRNA
going from the cytoplasm to the virus. For example, in AMV,
the relative concentration of tRNATrp changes from 1.4 to
32% (83). In HIV-1 produced from COS-7 cells transfected
with HIV-1 proviral DNA, both primer tRNA3
Lys and tRNA1,2
Lys
are selectively packaged, and the relative concentration of
tRNALys changes from 5 to 6% to 50 to 60% (52). In AKR-
MuLV, selective packaging of primer tRNAPro is less dramatic,
going from a relative cytoplasmic concentration of low-molec-
ular-weight RNA of 5 to 6% to 12 to 24% (83). tRNA3
Lys and
tRNA1,2
Lys are packaged into HIV-1 with equal efficiencies since
the tRNA3
Lys/tRNA1,2
Lys ratio in the virus reflects the cytoplasmic
ratio, even when the cytoplasmic ratio is altered (23). In
HIV-1, estimates of 20 molecules of tRNALys/virion (i.e., per 2
molecules of genomic RNA) have been reported (23), but
these numbers must remain estimates because the viral popu-
lation studied may not be homogeneous for packaging of either
genomic RNA or tRNALys. As with retroviruses, the primer
tRNAi
Met used in the Ty1 retrotransposon replication is also
selectively packaged into the VLPs, showing a 10- to 40-fold
increase in relative concentration (9, 64). In all of these cases,
there are no data on whether the absolute concentration of
primer tRNA (tRNA/volume) changes in going from the cyto-
plasm into the virus or VLP.
Reverse transcriptase sequences. Genomic RNA packaging
is not required for the incorporation of primer tRNA in ASV
(64), MuLV (44), or HIV-1 (30, 52). Several studies indicate
that RT sequences in retroviruses are involved in primer tRNA
packaging. In vitro studies using enzymatic and chemical
probes (5, 6, 69, 88) or cross-linking (56) have shown that the
FIG. 1. Replication cycle of retrovirus and retrotransposon elements. Most VLPs tend to remain intracellular, and most retroviruses have an extracellular stage.
The structure of the VLP is not as well characterized as that of retroviruses but probably also presents immature and mature forms which differ from each other in
their state of precursor protein proteolysis.
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anticodon, TCC, and D loops of free tRNA3
Lys interact with
mature RT. In vivo studies have also indicated the importance
of RT sequences in primer tRNA packaging. Selective pack-
aging of primer tRNA does not occur in RT-negative ASV (63)
or RSV (71), in a mutant Mo-MuLV which lacks 40% of the
RT sequence from the C terminus (42), or in an RT-negative
HIV-1 isolate (52). It is, however, not likely that the mature
RT itself is involved in primer tRNA packaging since viral
assembly occurs with larger precursor protein molecules which
are not cleaved until budding. Since the presence of RT is
required for primer tRNA packaging, this implies that the
Gag-Pol precursor is involved in this process since it contains
the RT sequences. Investigations into the packaging of
tRNALys into HIV have supported this hypothesis. It has been
shown that HIV particles composed of only Pr55gag do not
selectively package tRNALys while particles composed of both
Pr55gag and Pr160gag-pol do (52). Inhibition of HIV-1 protease
also does not prevent the select viral packaging of primer
tRNA3
Lys (52).
The results of an in vitro cross-linking study of a synthetic
tRNA3
Lys–HIV-1 RT complex support a possible interaction
between the tRNA3
Lys and the thumb and connection subdo-
mains of RT (56). In the in vitro study, no evidence for inter-
action of tRNA3
Lys was found for proteolytic RT fragments
containing primarily the finger or palm domains. On the other
hand, a carboxy-terminal p66 fragment (amino acid [aa] resi-
dues 357 to 560) containing both the carboxy half of the con-
nection domain and the RNase H domain interacted with the
59 terminus of tRNA3
Lys, while fragments from both p66 and
p51 (representing aa residues 230 to 356) containing both the
thumb and the amino portion of the connection domain were
found to interact with U36 in the anticodon of tRNA3
Lys. At-
tempts were also made to map a tRNALys binding site within
the HIV-1 RT sequences found in Pr160gag-pol by measuring
tRNA3
Lys packaging in viruses produced from COS cells trans-
fected with HIV proviral DNA mutated in various RT subdo-
mains. While it was found that mutations specifically in the
thumb and connection subdomains of RT resulted in de-
creased tRNA3
Lys packaging, these mutations also inhibited the
packaging of Pr160gag-pol (53) and therefore did not allow the
identification of a tRNA3
Lys binding site in RT.
Because mature RT interacts with primer tRNA during the
initiation of reverse transcription, RT sequences may also be
involved in facilitating genomic placement of primer tRNA. It
has been observed that the tRNA3
Lys acceptor stem (which
contains the sequences complementary to the PBS) is digested
by RNase A only in the presence of retroviral RT, suggesting
a partial destabilization of this region by the RT (69). Such
destabilization might be important for the genomic placement
of primer tRNA3
Lys in vivo. In ASV (63) and HIV-1 (13, 52),
the absence of RT protein and RT activity is correlated with
the absence of both selective primer tRNA packaging and
genomic placement of the tRNA, but it is difficult to determine
from this data if the lack of primer tRNA genomic placement
is due to the absence of RT or the absence of selective primer
tRNA packaging. Additionally, it should be noted that while
the absence of RT protein in MuLV also inhibits select primer
tRNA packaging, wild-type levels of primer tRNA are still
placed onto the viral genome; i.e., RT may not be involved in
primer tRNA placement in MuLV (42, 43). If RT protein does
facilitate annealing of primer tRNA to the PBS in avian and
human retroviruses, it probably does so as part of the Gag-Pol
protein, since genomic placement of primer tRNA can occur in
the absence of precursor processing in a PR-negative virion
(11, 26, 76).
Exceptions to the observation that primer tRNA packaging
in retroviruses is dependent on Gag-Pol packaging and inde-
pendent of genomic RNA packaging may exist. For example, in
HFV, which uses tRNA1,2
Lys as a primer, there is no Gag-Pol
precursor; the Pol protein is synthesized from a separate
spliced mRNA (90). In oncoviruses and lentiviruses, the Gag-
Pol precursor is believed to be carried into the virus via inter-
actions with the Gag precursor (59, 72, 74), and it may be that
in HFV a Gag-Pol complex, analogous to the Gag–Gag-Pol
complex in other viruses, is formed which can also carry the
tRNA1,2
Lys into the virion. However, no studies have been done
TABLE 1. Similarities and differences among selected retroviruses and retrotransposons
Retrovirus or
retrotransposon
Presence or absence of:
Primer tRNA Length of primer bindingsite (bases)Gag Gag-Pola Env Gag Cys-His boxb
ASLV 1 1 1 1 Trp 18
MuLV 1 1 1 1 Pro 18
HIV-1 1 1 1 1 Lys-3 18
HFV 1 2 1 2 Lys-1, 2 18
S. cerevisiae transposons
Ty1 (copia) 1 1 2 2 Met-i 10
Ty2 (copia) 1 1 2 2 Met-i 10
Ty3 (gypsy) 1 1 2 1 Met-i 8
Ty4 (copia) 1 1 2 1 Asn 18
Ty5 (copia) 1 1 2 1 Met-i fragment 13
Drosophila transposons
gypsy 1 1 1 2 Lys 11
17.6 (gypsy) 1 1 1 2 Ser 18
297 (gypsy) 1 1 1 2 Ser 18
tom (gypsy) 1 1 1 2 Ser 18
412 (gypsy) 1 1 2 2 Arg 18
copia 1 1 2 1 Met-i fragment 18
a In HFV, Pol is made from a singly spliced mRNA and is produced separately from Gag (91).
b In HFV, the presence of an NC sequence in the Gag protein is determined from it position toward the carboxy end of Gag (as in lentiviruses and oncoviruses) and
by the ability of this region to bind RNA in vitro, through glycine- and arginine-rich regions (89). Retrotransposon sequences are defined as coding for the NC protein
primarily because of the presence of a Cys-His box near the carboxy terminus of the Gag sequences, a position similar to that found for the NC of lentiviruses and
oncoviruses. The actual function of retrotransposon Gag carboxy-terminal sequences, with or without a Cys-His box, is not known, nor has the actual protein binding
to VLP RNA been evidenced.
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to determine if primer tRNA1,2
Lys packaging in HFV is selective
or is dependent on the Pol precursor. It has also been reported
that tRNAi
Met packaging in yeast Ty1 VLPs is severely dimin-
ished by mutations in either the PBS or regions downstream of
the PBS which are complementary to sequences in the TCC
and D arms (87). This report implies that primer tRNAi
Met
packaging depends on genomic RNA packaging, in contrast to
observations in retroviruses.
NC sequences. NC sequences have also been reported to
play an important role in retroviral processes such as primer
tRNA annealing, genomic RNA packaging and dimerization,
and minus-strand strong-stop cDNA strand transfer (12, 19).
There is also evidence that in HIV-1 the NC sequences in
Pr55gag may contribute to the tRNALys binding site associated
with viral packaging (22). HIV-1 NC (NCp7) contains two
subdomains known either as Cys-His boxes (because they con-
tain the CCHC motif, Cys-X2-Cys-X4-His-X4-Cys) or Zn21
fingers (because of their ability to bind Zn21). The positions of
the two Cys-His boxes in HIV-1 define other subdomains of
NCp7. From the N to the C terminus, these may be termed the
N-terminal subdomain, box 1, the linker subdomain, box 2, and
the C-terminal domain (7). The NCp7 mutant DK14-T50 has
both Cys-His boxes and the linker region between them de-
leted. COS cells transfected with this mutant proviral DNA
produce Pr55gag particles which package Pr160gag-pol but not
tRNALys. tRNALys packaging is rescued by cotransfection with
a plasmid coding for wild-type Pr55gag (and not with a plasmid
coding for wild-type Pr160gag-pol), indicating a possible role of
NC sequences in the Gag precursor in forming the tRNALys
binding site, possibly as part of a Pr55gag-Pr160gag-pol complex
(22).
HIV-1 NC protein also facilitates the annealing of tRNA3
Lys
to in vitro-transcribed genomic RNA sequences (16), probably
by unwinding the secondary structure of tRNA3
Lys in vitro (34).
Similar observations have been made in RSV and Mo-MuLV;
NC promotes the annealing of tRNATrp and tRNAPro to the
PBSs of the RSV and Mo-MuLV genomic RNA, respectively
(64). The promotion of tRNA3
Lys placement by NC in vitro
occurs in an NC concentration-dependent manner (46), and a
recent study indicates that the NC-tRNA3
Lys interaction is non-
specific, i.e., it results from the general ability of NC to interact
with RNA (55). For both Mo-MuLV (15) and HIV-1 (16, 39)
it has been reported that the in vitro annealing of primer tRNA
is independent of the presence of the Cys-His boxes but de-
pends on the presence of the amino acids flanking the first, or
only, Cys-His box. These observations have recently been con-
firmed in vivo for HIV-1 (25).
Whether nucleocapsid plays such an important role in spu-
maviruses or in retrotransposons is unclear. All retrovirus NC
proteins contain one or two Cys-His boxes, with the exception
of the NCs of HFV and simian foamy virus, which do not
contain Cys-His box (66). The presence of NC sequences in the
carboxy region of HFV Gag protein is indicated by the ability
of this region to bind to RNA in vitro through glycine- and
arginine-rich regions (91). Many retrotransposon Gag proteins
synthesized for VLP production also do not contain this
metal finger motif. As for the Gag proteins synthesized by
the five Ty transposons, those of Ty1 and Ty2 do not have a
Cys-His box while those of Ty3 to Ty5 do. None of the four
Drosophila gypsy elements (17.6, 297, tom, and gypsy) has
this metal finger motif. The function of retrotransposon Gag
carboxy-terminal sequences, with or without a Cys-His box,
is not known.
SIGNALS ON PRIMER tRNA ASSOCIATED WITH ITS
PACKAGING, GENOMIC PLACEMENT, AND
PRIMING FUNCTION
The signals on the primer tRNA which target it for viral
packaging are not known. In vitro studies on the interaction of
purified tRNA3
Lys with mature HIV RT have indicated that an
interaction between the anticodon of the tRNA and RT occurs
(5, 6, 69, 88). In HIV-1, mutations in the tRNA3
Lys anticodon
(SUU changed to CUA, where S 5 mcm5S2U [5-methoxycar-
bonylmethyl-2-thiouridine]) prevent the mutant tRNA from
acting as a primer in vivo (24) but do not prevent viral pack-
aging of this tRNA (23, 24). Similarly, tRNA3
Lys and tRNA1,2
Lys
are packaged into HIV-1 with the same efficiency (23) but have
different anticodons (SUU and CUU, respectively). The insen-
sitivity of tRNALys packaging to the anticodon sequence should
not be surprising since the interaction of the tRNA with ma-
ture RT may be very different from the interaction with the pro-
teins involved in tRNALys packaging, Pr160gag-pol and Pr55gag.
Although no common property shared by primer tRNAs has
been associated with their ability to act as primers, one case has
been reported in which a specific modification of tRNATrp was
found to influence its ability to be packaged into AMV (33).
Two major tRNATrp species have been identified in avian cells,
which differ by a methylation of nucleotide 7 in the amino acid
acceptor stem: G or m2G. Only the nonmethylated species is
packaged and used as the primer for avian retrovirus reverse
transcription. The methylation of G to m2G may thus prevent
the recognition of tRNATrp by a retroviral protein(s) respon-
sible for the selective packaging of the primer tRNATrp.
Boeke and his colleagues have utilized the powerful genetic
capabilities of the yeast S. cerevisiae to analyze the effect of
mutations in tRNAi
Met on its ability to participate in the Ty1
retrotransposon replication cycle (32). A strain of S. cerevisiae
was created that did not contain the four tRNAi
Met genes of
this yeast. Translation was allowed through the introduction of
a plasmid containing a mutant tRNAi
Met gene capable of pro-
ducing a tRNAi
Met which could participate in translation but
not in retrotransposon replication. The ability of a genetically
marked Ty1 transposon (also coded for by this plasmid) to
transpose was examined when a second plasmid bearing a
mutant tRNAi
Met gene was introduced. Using this system, they
found that single mutations in the acceptor stem region com-
plementary to the PBS, and mutations in the TCC and D arms
of tRNAi
Met, inhibited transposition while mutations in the
anticodon arm did not. Unfortunately, the steps in the retro-
transposon replication cycle which are inhibited by these mu-
tations are not yet known.
Since in the cell tRNA is found in complexes with proteins
associated with translation, one of these cellular proteins could
play a role in facilitating an interaction between the primer
tRNA and the viral or VLP proteins. In eukaryotic translation,
tRNA is part of a channeled cycle (75) and aminoacyl-tRNAs
are directly transferred from aminoacyl-tRNA synthetase to
the elongation factor eEF1a, which carries tRNAs to the ri-
bosomes. After peptide bond formation, the deacylated tRNAs
are transferred back, via eEF1a, to their cognate synthetases
for recharging with amino acids. The interaction between a
viral precursor protein and primer tRNA might occur at the
polysome, where both components are concentrated, and the
interaction could be initially with a tRNA binding protein such
as eEF1a or aminoacyl-tRNA synthetase. It has been reported
that while all detectable tRNALys in an HIV-1-infected cell is
acylated, all detectable tRNALys in HIV-1 is deacylated (23), a
state required for tRNALys to function as a primer for RT. It
is possible that a tRNALys molecule is bound to a partially
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synthesized precursor protein immediately after donating its
lysine to the growing peptide chain on the polysome, but there
is currently no evidence to indicate whether tRNALys is deacy-
lated before or after its entry into the virion.
INTERACTION BETWEEN THE PRIMER tRNA AND
GENOMIC RNA SEQUENCES, AND INITIATION OF
REVERSE TRANSCRIPTION
Primer tRNA is found in the virus both in a free state and
bound to the viral genome (63). Although the incorporation of
most of the primer tRNA molecules into the virus occurs
independently of genomic RNA packaging (32, 36, 46), it is not
known whether the actual primer tRNA molecule bound to the
viral RNA genome is placed onto the PBS before or after
packaging. Some of the postulated interactions between
primer tRNA and the region around the PBS are shown for the
tRNA3
Lys and HIV-1 genomic RNA in Fig. 2 (modified from
reference 3). The 39-terminal nucleotides of the primer tRNA
are complementary to the nucleotides comprising the PBS, and
studies in HIV-1 (80), MuLV-based retroviral vectors (49), and
the Ty1 retrotransposon (32) have shown that a minimum
degree of complementarity must be maintained to achieve
efficient reverse transcription.
Studies with both HIV-1 and ALV have shown that the PBS
sequence is not in itself sufficient to determine primer tRNA
identity. Transfection of proviral DNAs with PBS sequences
that are complementary to tRNAs other than the natural
primer tRNA yielded virus with initially slow replication kinet-
ics in studies using either HIV-1 (14, 45, 81) or ALV (85).
However, the mutant genomes eventually revert back to their
respective wild-type PBS sequences and the revertant virus
then grows at wild-type rates. The reversion to the wild-type
PBS sequence probably results from the reverse transcription
of the 39 18 nucleotides of the natural primer tRNA which
occurs during the synthesis of plus-strand strong-stop cDNA,
as shown in step 5 of Fig. 3. After the 39-terminal nucleotides
of the tRNA primer are copied, strand transfer of this strong-
stop DNA to the 59 terminus of the minus-strand DNA (step 6)
results in annealing of the newly generated PBS sequences to
the complementary PBS sequences in the minus-strand DNA.
This model, which predicts that the tRNA 39-terminal se-
quences determine the sequence of the newly generated PBS,
is used to explain how PBS sequences made complementary to
a nonprimer retroviral tRNA eventually revert back to se-
quences complementary to a more favored natural primer
tRNA.
The method of generating a new PBS may, however, be
different in some retrotransposons. Using the engineered yeast
strain (32) described above, a tRNAi
Met mutated at position 7
in the 39-terminal sequence complementary to the PBS was
used as the sole primer tRNA for Ty1 reverse transcription.
The PBS retained the wild-type sequence; i.e., the mutant
tRNAi
Met did not appear to contribute to the generation of the
new PBS (40). This implies that the new PBS is inherited from
the old PBS sequence rather than the primer tRNA. This could
be accomplished as follows: if the first strand transfer in step 2
of Fig. 3 went to another copy of undegraded genomic RNA,
FIG. 2. Proposed regions of base pairing between tRNA3Lys and the HIV-1
genome. This figure is modified from one of Arts et al. (3). In addition to the PBS
interaction, other regions in the viral genomic RNA may interact with the tRNA.
These include the A-rich regions upstream (28, 30) and downstream (38) of the
PBS interacting with the anticodon loop (shown by the two arrows), as well as an
interaction of the TCC loop with a U5 region upstream of the PBS (1, 2).
FIG. 3. Reverse transcription of retroviral genomic RNA into double-
stranded proviral DNA. This figure is modified with permission from the authors
of reference 77a. Step 1: annealing of primer tRNA to the PBS, and synthesis of
minus-strand strong-stop cDNA, with the resulting degradation of R and U5
RNA by the RNase H activity of the reverse transcriptase. Step 2: the first strand
transfer, in which minus-strand strong-stop cDNA is annealed to the 59 terminus
of the genomic RNA via R-R9 hybridization. Steps 3 and 4: further synthesis of
minus-strand cDNA, during which the genomic RNA is further degraded by
RNase H. A small piece of RNA, the polypurine tract (PPT), remains unde-
graded and serves as the primer for plus-strand strong-stop cDNA (step 5). Step
5: termination of plus-strand strong-stop cDNA synthesis 18 nucleotides into the
primer tRNA, thereby generating a new PBS sequence; the tRNA is released
from the minus-strand cDNA. Step 6: the second strand transfer, in which
plus-strand strong-stop cDNA is annealed to the 39 terminus of minus-strand
cDNA via PBS-PBS9 hybridization. Step 7: completion of synthesis of double-
stranded proviral DNA.
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then the resulting minus-strand cDNA synthesized would con-
tain R9-U59 at its 39 end. In step 5, plus-strand synthesis would
terminate before tRNA sequences are copied, and the second
strand transfer seen in step 6 would be to full-length minus-
strand cDNA; i.e., pairing would be between R-U5 and R9-
U59. Further plus-strand cDNA synthesis would generate a
new PBS sequence from PBS9 in the minus strand. This mech-
anism of reverse transcription is different from that shown in
Fig. 3; i.e., the first strand transfer in step 2 would be inter-
molecular rather than intramolecular, and plus-strand strong-
stop cDNA would terminate before copying tRNA sequences.
Although there is no direct evidence for the presence of two
copies of genomic RNA in the VLPs, as in retroviruses, some
genetic evidence indicates that there is more than one full-
length RNA molecule per particle; i.e., data indicating that the
equivalent of retroviral recombination happens at a very high
frequency have been reported (8). There is also evidence in
Ty1 of some plus-strand strong-stop cDNA terminating before
using tRNA sequences as templates (86).
The conversion of an altered PBS to one complementary to
the natural primer tRNA, as seen in HIV-1 and ALV, may not
occur in some MuLV systems. For example, Lund et al. (50)
showed that a replication-defective retroviral vector derived
from MuLV could use various cellular tRNAs as primers to
replicate with equal efficiencies. This vector contained the
LTRs, PBS, and some leader sequence of MuLV, as well as a
neomycin gene, but could not code for viral proteins, which
were provided by an RNA packaging cell line. The resulting
VLPs could undergo one round of infection, and resulting
G418-resistant cells were used as evidence of the occurrence of
reverse transcription of the infecting RNA genome. It was
found that vectors with PBSs complementary to different
tRNAs could produce as many G418-resistant cells as one with
the natural PBS complementary to tRNAPro. The MuLV-
based retroviral vector has a greater ability to use alternate
primer tRNAs than do the ALV and HIV-1 retroviruses, and
this could reflect the finding noted earlier that the restriction
on the type of primer tRNA used in MuLVs may not be as
stringent as for HIV or avian retroviruses. However, a poten-
tial problem when using this retroviral vector system to study
primer tRNA packaging and initiation of reverse transcription
is that while tRNAs other than tRNAPro can be used as prim-
ers with similar efficiencies, it is not clear whether the retroviral
vector genome using the natural primer tRNAPro is itself being
efficiently reverse transcribed in this artificial system compared
with wild-type MuLV. Also, because this system uses only one
round of infection, it may not be sensitive to subtle differences
arising when using an alternate tRNA instead of the natural
primer tRNA.
The reversion of altered PBSs in HIV and ALV to the
natural wild-type PBS suggests that there are factors other
than just the PBS which influence the choice of the primer
tRNA used. It has been reported that regions in the genomic
RNA other than the PBS interact with the primer tRNA, and
these interactions are shown in Fig. 2 for the tRNA3
Lys-HIV
genomic RNA complex. The existence of an interaction of
USUU in the anticodon loop of tRNA3
Lys with the A-rich loop
in this U5 stem–A-rich loop was first reported by Ehresmann
and colleagues (29), who demonstrated this interaction
through a combination of chemical and enzymatic probing and
computer modeling (27). The anticodon loop has also been
proposed to interact with another A-rich region downstream of
the PBS (37). Both interactions are shown by arrows in Fig. 2.
Also shown is a proposed interaction between the TCC loop
and U5 sequences which were first proposed for primer
tRNATrp based on studies of its interaction with the genomes
of ASV and ALV (1, 2).
Although all lentiviruses examined (HIV-1, HIV-2, simian
immunodeficiency virus, feline immunodeficiency virus, and
equine infectious anemia virus) use tRNA3
Lys as a primer (41),
only HIV-1 contains an A-rich loop in the U5 stem-loop. In
vitro, reverse transcription using homologous RT and genomic
RNA for each of these lentiviruses can be resolved into initi-
ation and elongation phases, and U5 stem-loop structures may
be involved in the transition between these two stages. The
initiation phase is manifest by an initial buildup of 1- to 12-base
DNA extensions of the tRNA3
Lys, depending on the source of
viral RNA; i.e., the length of these extensions appears to be
correlated with a stem-loop structure upstream of the PBS (4).
In the case of HIV-1, the in vitro extensions are 1 to 6 bases in
length. Evidence for a discrete initiation stage of HIV-1 re-
verse transcription has also been found in vivo. In HIV-1
produced from either transfected COS-7 cells or a variety of
stably infected cell lines (H9, CEM-SS, U937, and PLB), the
tRNA3
Lys annealed to the PBS appears to exist in two forms:
unextended tRNA3
Lys and tRNA3
Lys extended by the first two
nucleotides added during reverse transcription, dCMP and
TMP (26). As shown in Fig. 2, the 2-base extension would
extend to the first GC base pair in the stem.
A U5 stem-loop structure immediately upstream of the PBS
in RSV has been reported (9). Mutations disrupting this struc-
ture inhibit reverse transcription in vivo. In vitro experiments
indicate that the disruption does not reduce tRNATrp place-
ment on the PBS but does reduce the initiation of reverse
transcription. Also, a deletion in the 39 part of the U5 region
near the PBS in Mo-MuLV causes an inhibition of viral cDNA
synthesis in vivo, but in vitro experiments indicate that neither
primer tRNA placement nor initiation of reverse transcription
was impaired (57). No evidence for the existence of short DNA
extensions in avian or murine retroviruses has been reported.
At the other extreme, it has been estimated that 10 to 15% of
mature-HFV particles contain double-stranded cDNAs ap-
proaching full length (90), an indication of the occurrence of
reverse transcription prior to HFV infection of target cells.
Deletion of the four consecutive A’s in the U5 stem-loop of
HIV-1 does not affect tRNA3
Lys genomic placement, either in
vitro (4, 28) or in vivo (25, 47). Neither is the early pausing of
reverse transcription diminished in vitro (4) or in vivo (25) at
low RT-to-primer/template (1:2) ratios, probably because the
stem structure is still maintained. When the stem structure is
destabilized by using a 9-base preextended tRNA3
Lys as the
primer, pausing disappears (4). In vivo, HIV-1 containing a
deletion of the 4 A’s shows decreased reverse transcription and
slower replication kinetics, which increase over time after the
reversion of two G’s to A’s in the region of the stem-loop
structure (47). The initiation and elongation phases of reverse
transcription have been associated with low and high proces-
sivity of RT, respectively (38), and in vivo, destabilization of
the A-rich loop seems to result in decreased elongation due to
lower RT processivity (25). The ability of HIV RT to interact
with the tRNA3
Lys anticodon bound to the A-rich loop may
allow the enzyme to change its conformation after a short
cDNA extension, but why such an interaction is required only
in HIV-1 is unknown.
Interestingly, the A-rich loop can play a role in determining
the identity of the primer tRNA used in HIV-1. Morrow’s
group had found that infection of cells with HIV-1 containing
a PBS complementary to tRNAHis rather than tRNA3
Lys results
in an initial low rate of virus replication followed at later stages
by rates of virus production approaching those of the wild-type
virus. The increased viral replication is correlated with rever-
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sion of the tRNAHis PBS to a PBS complementary to tRNA3
Lys,
implying the eventual use of tRNA3
Lys again as the primer (81).
However, when the A-rich loop as well was altered so that it
was complementary to the tRNAHis anticodon, the tRNAHis
PBS became stabilized in the viral population (79) and wild-
type viral replication rates occurred (although some other mu-
tations which may be further required for this stabilization also
arose in the region near the A-rich loop). Similarly, altering
both the PBS and the U5 stem–A-rich loop in HIV-1 genomic
RNA so that they were complementary to the acceptor stem
and anticodon loop of tRNAi
Met, respectively, resulted in the
stable use of tRNAi
Met as a primer (31). These results clearly
indicate a role for the A-rich loop in allowing a tRNA other
than tRNA3
Lys to be used as a primer for reverse transcription
in HIV-1. Since the deletion of the A-rich loop does not alter
genomic placement of primer tRNA3
Lys, it seems likely that
altering the loop so that it interacts with the new primer tRNA
determined by the PBS sequences probably allows a more
highly processive elongation phase of reverse transcription to
proceed. From this interpretation, it might be predicted that
altering the PBS in a virus not containing such an anticodon–
stem-loop interaction would be enough to create a new primer
tRNA. This has not turned out to be the case for ALV, in
which altered PBSs tend to revert to the native tRNATrp PBS;
this may be due to other required interactions between
tRNATrp and the genomic RNA, such as the interaction shown
to occur between the TCC loop and U5 region in ASV and
ALV (1, 2).
UNANSWERED QUESTIONS
The use of tRNAs as primers for reverse transcription may
reflect an ancient function in the RNA world. This is discussed
in the genomic tag hypothesis of Maizels and Weiner (51),
which proposes that in the ancient world, when the major
replicating macromolecule may have been RNA, tRNA-like
structures were tags at the 39 termini of the RNA genomes,
serving as primers for the synthesis of complementary RNA
strands. It is not clear today why only a limited number of such
primer tRNAs have been identified. Do they have a common
property associated with their ability to act as primers, a prop-
erty even shared with 59 and internal tRNAi
Met fragments used
as primers in some retrotransposons, or is the number of
tRNAs used as primers limited only by the evolution of other
components of the priming apparatus to operate most effi-
ciently with select tRNAs?
How are the tRNAs selectively packaged? In HIV-1, both
Gag and Gag-Pol precursors seem to be involved in carrying
primer tRNA into the virus, independently of genomic RNA
packaging. In HFV, however, Pol is made separately from Gag.
Are Gag–Gag-Pol and Gag-Pol complexes formed in HIV-1
and HFV, respectively, and do they perform similar functions?
What is the role of genomic RNA in primer tRNA packaging
in Ty1, for which mutations in the packaged RNA seem to
affect primer tRNA packaging? What signals target the tRNA
for packaging? Are there targeting signals within either the
tRNA’s primary sequence or its molecular conformation, or do
viral proteins initially interact with tRNA-binding proteins
such as the aminoacyl-tRNA synthetase? Could this mean that
only tRNAs participating in protein synthesis are capable of
interacting with viral proteins, and does this interaction occur
at the polysome during the synthesis of Gag and Gag-Pol? The
study of primer tRNA packaging is a study in viral assembly,
and the mechanism by which a primer tRNA-viral protein
complex is carried to the site of viral assembly is not known.
In fact, it remains unclear whether selective packaging of
primer tRNA is required for its efficient genomic placement. In
MuLV, disruption of selective packaging of tRNAPro in an
RT-negative virion does not affect tRNAPro genomic place-
ment. On the other hand, RT-negative HIV-1 and ALV virions
show neither selective incorporation nor genomic placement of
primer tRNA, but inefficient genomic placement could be due
to the absence of RT sequences rather than the absence of
selective packaging. In HIV-1, altering both the PBS and the
A-rich loop so that they are complementary to the 39-terminal
nucleotides and anticodon loop, respectively, of tRNAHis re-
sults in the stable use of tRNAHis as a primer, without evidence
of an increase in its relative concentration in the virion. If
selective packaging of primer tRNA is not required, why does
this packaging occur in most retroviral and retrotransposon
systems examined?
Are nucleocapsid sequences required for genomic place-
ment of primer tRNA? The answer appears to be “yes” in
HIV-1 as well as in avian and murine retroviruses, but what
about HFV and retrotransposons, which do not have any Cys-
His box? In oncoviruses and lentiviruses, the Cys-His box is a
landmark for nucleocapsid sequences, but it is the amino acids
flanking these boxes, rather than the boxes themselves, which
seem to be responsible for annealing primer tRNA to the PBS.
Are there sequences near the carboxy termini of HFV or
retrotranspon Gag proteins which perform the same function
in these systems as nucleocapsid sequences in other retrovi-
ruses?
Clearly, further studies are required to answer these ques-
tions, and the comparison of results from several different
retroviral and retrotransposon systems may eventually reveal
simple underlying principles behind the apparent diversity of
primer tRNA processing and function in these systems.
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